MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
227.21%
Quick Ratio
227.21%
Cash Ratio
224.82%
Debt to Asset Ratio
44.01%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Other current assets
Liabilities Breakdown
    • Additional paid in capital
    • Accumulated deficit
    • Employee compensation and benefi...
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
25,130 31,634 35,442 26,793
Other current assets
268 75 145 214
Total current assets
25,398 31,709 35,587 27,007
Total assets
25,398 31,709 35,587 27,007
Accounts payable
4,695 6,274 6,439 4,977
Payable offering costs
NaN NaN 75 75
Accrued liabilities
36 115 65 2
Employee compensation and benefits
6,447 6,907 4,998 5,081
Total current liabilities
11,178 13,296 11,577 10,135
Total liabilities
11,178 13,296 11,577 10,135
Additional paid in capital
119,957 118,100 116,383 101,783
Accumulated deficit
-105,737 -99,687 -92,373 -84,911
Total shareholders' equity
14,220 18,413 24,010 16,872
Total liabilities and shareholders' equity
25,398 31,709 35,587 27,007
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$25,130K Other current assets$268K Total current assets$25,398K Total assets$25,398K Total liabilities andshareholders' equity$25,398K Total shareholders'equity$14,220K Total liabilities$11,178K Accumulated deficit-$105,737K Additional paid in capital$119,957K Total currentliabilities$11,178K Employee compensationand benefits$6,447K Accounts payable$4,695K Accrued liabilities$36K

Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma, Inc. (NVCT)